Mumbai, May 28 : Pharma Major, Sun Pharma had earler announced about the Distribution Services Agreement entered into between AstraZeneca Pharma India Limited and Sun Pharma Laboratories its wholly owned subsidiary for the distribution of Dapagliflozin, an innovative Type 2 diabetes medicine, in India.
Under the said agreement, AstraZeneca India had granted rights to Sun Pharma to promote and distribute Dapagliflozin under the brand name “Oxra”. Sun Pharma also gained the rights to promote and distribute the combination of Dapagliflozin with Metformin under the brand name “Oxramet” and the combination of Dapagliflozin and Saxagliptin under the brand name “Oxraduo”. The said Distribution Agreement had conferred only a license to Sun Pharma for the use of trademarks “Oxra”, “Oxramet” and “Oxraduo” in India.
Sun Pharma has now acquired the rights to Trademarks “Oxra”, “Oxramet” and “Oxraduo” in India from AstraZeneca AB, Sweden, parent company of AstraZeneca Pharma India Limited, with effect from May 28, 2021. In addition Sun Pharma has also taken a patent license to manufacture and commercialize Dapagliflozin and Dapagliflozin with Metformin combination in India from AstraZeneca AB with effect from May 28, 2021.
Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from May 28, 2021.
Under the Transition Supply Agreement, AstraZeneca India will supply Dapagliflozin and the combination of Dapagliflozin with Metformin to Sun Pharma until such period of time as mutually agreed between the parties, post which all supplies to Sun Pharma from AstraZeneca India shall cease.(UNI)